These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38961765)

  • 1. Virological characteristics of the SARS-CoV-2 Omicron EG.5.1 variant.
    Tsujino S; Deguchi S; Nomai T; Padilla-Blanco M; Plianchaisuk A; Wang L; Begum MM; Uriu K; Mizuma K; Nao N; Kojima I; Tsubo T; Li J; Matsumura Y; Nagao M; Oda Y; Tsuda M; Anraku Y; Kita S; Yajima H; Sasaki-Tabata K; Guo Z; Hinay AA; Yoshimatsu K; Yamamoto Y; Nagamoto T; Asakura H; Nagashima M; Sadamasu K; Yoshimura K; Nasser H; Jonathan M; Putri O; Kim Y; Chen L; Suzuki R; Tamura T; Maenaka K; Irie T; Matsuno K; Tanaka S; Ito J; Ikeda T; Takayama K; Zahradnik J; Hashiguchi T; Fukuhara T; Sato K;
    Microbiol Immunol; 2024 Sep; 68(9):305-330. PubMed ID: 38961765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants.
    Tamura T; Ito J; Uriu K; Zahradnik J; Kida I; Anraku Y; Nasser H; Shofa M; Oda Y; Lytras S; Nao N; Itakura Y; Deguchi S; Suzuki R; Wang L; Begum MM; Kita S; Yajima H; Sasaki J; Sasaki-Tabata K; Shimizu R; Tsuda M; Kosugi Y; Fujita S; Pan L; Sauter D; Yoshimatsu K; Suzuki S; Asakura H; Nagashima M; Sadamasu K; Yoshimura K; Yamamoto Y; Nagamoto T; Schreiber G; Maenaka K; ; Hashiguchi T; Ikeda T; Fukuhara T; Saito A; Tanaka S; Matsuno K; Takayama K; Sato K
    Nat Commun; 2023 May; 14(1):2800. PubMed ID: 37193706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virological and Mitochondriopathogical Characteristics of the SARS-CoV-2 Omicron XBB.1.16 Spike.
    Fang L; Kang X; Hong Q; Xue C; Pan L; Chen J; Tang C; Sun L; Xu X; Yuan J; Du Y; Xu A
    ACS Appl Mater Interfaces; 2024 Jun; 16(23):29716-29727. PubMed ID: 38814480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolutionary and Phylogenetic Dynamics of SARS-CoV-2 Variants: A Genetic Comparative Study of Taiyuan and Wuhan Cities of China.
    Hussain B; Wu C
    Viruses; 2024 Jun; 16(6):. PubMed ID: 38932199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 Omicron XBB lineage spike structures, conformations, antigenicity, and receptor recognition.
    Zhang QE; Lindenberger J; Parsons RJ; Thakur B; Parks R; Park CS; Huang X; Sammour S; Janowska K; Spence TN; Edwards RJ; Martin M; Williams WB; Gobeil S; Montefiori DC; Korber B; Saunders KO; Haynes BF; Henderson R; Acharya P
    Mol Cell; 2024 Jul; 84(14):2747-2764.e7. PubMed ID: 39059371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ensemble-Based Mutational Profiling and Network Analysis of the SARS-CoV-2 Spike Omicron XBB Lineages for Interactions with the ACE2 Receptor and Antibodies: Cooperation of Binding Hotspots in Mediating Epistatic Couplings Underlies Binding Mechanism and Immune Escape.
    Raisinghani N; Alshahrani M; Gupta G; Verkhivker G
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
    Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L
    J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virological characteristics of the SARS-CoV-2 BA.2.86 variant.
    Tamura T; Mizuma K; Nasser H; Deguchi S; Padilla-Blanco M; Oda Y; Uriu K; Tolentino JEM; Tsujino S; Suzuki R; Kojima I; Nao N; Shimizu R; Wang L; Tsuda M; Jonathan M; Kosugi Y; Guo Z; Hinay AA; Putri O; Kim Y; Tanaka YL; Asakura H; Nagashima M; Sadamasu K; Yoshimura K; ; Saito A; Ito J; Irie T; Tanaka S; Zahradnik J; Ikeda T; Takayama K; Matsuno K; Fukuhara T; Sato K
    Cell Host Microbe; 2024 Feb; 32(2):170-180.e12. PubMed ID: 38280382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effective Inhibitory Concentration of Interferon-β Correlates with Infectivity and Replication Fitness of SARS-CoV-2 Variants.
    Singh J; Anantharaj A; Kumar P; Pandey R; Pandey AK; Medigeshi GR
    J Interferon Cytokine Res; 2024 Jul; 44(7):325-333. PubMed ID: 38557204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant.
    Saito A; Tamura T; Zahradnik J; Deguchi S; Tabata K; Anraku Y; Kimura I; Ito J; Yamasoba D; Nasser H; Toyoda M; Nagata K; Uriu K; Kosugi Y; Fujita S; Shofa M; Monira Begum M; Shimizu R; Oda Y; Suzuki R; Ito H; Nao N; Wang L; Tsuda M; Yoshimatsu K; Kuramochi J; Kita S; Sasaki-Tabata K; Fukuhara H; Maenaka K; Yamamoto Y; Nagamoto T; Asakura H; Nagashima M; Sadamasu K; Yoshimura K; Ueno T; Schreiber G; Takaori-Kondo A; ; Shirakawa K; Sawa H; Irie T; Hashiguchi T; Takayama K; Matsuno K; Tanaka S; Ikeda T; Fukuhara T; Sato K
    Cell Host Microbe; 2022 Nov; 30(11):1540-1555.e15. PubMed ID: 36272413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant.
    Tamura T; Irie T; Deguchi S; Yajima H; Tsuda M; Nasser H; Mizuma K; Plianchaisuk A; Suzuki S; Uriu K; Begum MM; Shimizu R; Jonathan M; Suzuki R; Kondo T; Ito H; Kamiyama A; Yoshimatsu K; Shofa M; Hashimoto R; Anraku Y; Kimura KT; Kita S; Sasaki J; Sasaki-Tabata K; Maenaka K; Nao N; Wang L; Oda Y; ; Ikeda T; Saito A; Matsuno K; Ito J; Tanaka S; Sato K; Hashiguchi T; Takayama K; Fukuhara T
    Nat Commun; 2024 Feb; 15(1):1176. PubMed ID: 38332154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A bispecific antibody exhibits broad neutralization against SARS-CoV-2 Omicron variants XBB.1.16, BQ.1.1 and sarbecoviruses.
    Wang Y; Hao A; Ji P; Ma Y; Zhang Z; Chen J; Mao Q; Xiong X; Rehati P; Wang Y; Wang Y; Wen Y; Lu L; Chen Z; Zhao J; Wu F; Huang J; Sun L
    Nat Commun; 2024 Jun; 15(1):5127. PubMed ID: 38879565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epitopes of an antibody that neutralizes a wide range of SARS-CoV-2 variants in a conserved subdomain 1 of the spike protein.
    Ishimaru H; Nishimura M; Shigematsu H; Marini MI; Hasegawa N; Takamiya R; Iwata S; Mori Y
    J Virol; 2024 May; 98(5):e0041624. PubMed ID: 38624232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spatiotemporal dynamics and epidemiological impact of SARS-CoV-2 XBB lineage dissemination in Brazil in 2023.
    Arantes I; Gomes M; Ito K; Sarafim S; Gräf T; Miyajima F; Khouri R; de Carvalho FC; de Almeida WAF; Siqueira MM; Resende PC; Naveca FG; Bello G;
    Microbiol Spectr; 2024 Mar; 12(3):e0383123. PubMed ID: 38315011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple mutations of SARS-CoV-2 Omicron BA.2 variant orchestrate its virological characteristics.
    Kimura I; Yamasoba D; Nasser H; Ito H; Zahradnik J; Wu J; Fujita S; Uriu K; Sasaki J; Tamura T; Suzuki R; Deguchi S; Plianchaisuk A; Yoshimatsu K; Kazuma Y; Mitoma S; Schreiber G; Asakura H; Nagashima M; Sadamasu K; Yoshimura K; Takaori-Kondo A; ; Ito J; Shirakawa K; Takayama K; Irie T; Hashiguchi T; Nakagawa S; Fukuhara T; Saito A; Ikeda T; Sato K
    J Virol; 2023 Oct; 97(10):e0101123. PubMed ID: 37796123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of mutations in SARS-CoV-2 recombinant sub-variant XBB.1.16 on the binding affinity with human ACE2 receptor.
    Tariq SS; Zia K; Nur-E-Alam M; Nerukh D; Farafonov VS; Ul-Haq Z
    J Mol Graph Model; 2024 Sep; 131():108813. PubMed ID: 38885553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant.
    Suzuki R; Yamasoba D; Kimura I; Wang L; Kishimoto M; Ito J; Morioka Y; Nao N; Nasser H; Uriu K; Kosugi Y; Tsuda M; Orba Y; Sasaki M; Shimizu R; Kawabata R; Yoshimatsu K; Asakura H; Nagashima M; Sadamasu K; Yoshimura K; ; Sawa H; Ikeda T; Irie T; Matsuno K; Tanaka S; Fukuhara T; Sato K
    Nature; 2022 Mar; 603(7902):700-705. PubMed ID: 35104835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralization sensitivity of SARS-CoV-2 Omicron variants FL.1 and GE.1 by therapeutic antibodies and XBB sera.
    Lee J; Naoe Y; Bang U; Nakagama Y; Saito A; Kido Y; Hotta A
    Virology; 2024 Jul; 595():110067. PubMed ID: 38653156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temperature-dependent Spike-ACE2 interaction of Omicron subvariants is associated with viral transmission.
    Benlarbi M; Ding S; Bélanger É; Tauzin A; Poujol R; Medjahed H; El Ferri O; Bo Y; Bourassa C; Hussin J; Fafard J; Pazgier M; Levade I; Abrams C; Côté M; Finzi A
    mBio; 2024 Aug; 15(8):e0090724. PubMed ID: 38953636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters.
    Soudani N; Bricker TL; Darling T; Seehra K; Patel N; Guebre-Xabier M; Smith G; Davis-Gardner M; Suthar MS; Ellebedy AH; Boon ACM
    J Virol; 2024 Sep; ():e0052824. PubMed ID: 39230305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.